CTI BioPharma Corp. will tap a huge percentage of the myelofibrosis market poorly served by existing therapies with the approval of its JAK2/IRAK1 inhibitor, Vonjo (pacritinib), as it prepares to make the drug available in less than two weeks.
The US Food and Drug Administration gave the drug accelerated approval on 28 February for patients with intermediate- or high-risk...







